A SIMPLE KEY FOR NINTEDANIB UNVEILED

There have been no clinically significant dissimilarities in the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when applied concomitantly with finerenone. A number of doses of forty mg finerenone when-every day experienced no clinically related effect on AUC or Cmax from the BCRP and OATP substrate rosuva